Bicycle Therapeutics (BCYC) risk factors
Item 1A of every Bicycle Therapeutics plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors74 risks11 new8 dropped21 reworded
Bicycle Therapeutics implemented severe workforce reductions and strategic reprioritization affecting its clinical portfolio in 2025 and 2026. Global trade tensions, tariffs, and FDA disruptions introduced new regulatory compliance uncertainties. Partnership changes and reliance on third-party vendors created heightened operational risks.
Filed Mar 17, 2026 - FY2024 10-K risk factors71 risks
Bicycle Therapeutics relies heavily on early-stage clinical programs like zelenectide pevedotin and external research collaborations with companies such as Bayer and Novartis. The company has a substantial accumulated deficit of $680.8 million and faces significant risks regarding ongoing losses and future capital needs.
Filed Feb 25, 2025